The new Director General of the ABPI has been named as Dr Richard Barker. He takes over from Dr Trevor Jones, who is retiring on 31 August. Dr Jones has held the position since 1994, leaving Wellcome to join the industry group.
Dr Barker is the founder and president of New Medicine Partners, an advisory firm assisting pharmaceutical and biotechnology companies to address issues of strategy, product development and commercialisation.
He is also chairman of Molecular Staging, a genomics and proteomics company serving academic researchers and major pharmaceutical companies; a member of the board of Exact Sciences, which applies genomics to colon cancer screening; and a member of the advisory board for paediatric devices for the Children's Hospital, Boston.
Formerly, Dr Barker was CEO of Chiron's diagnostic division, general manager of IBM's worldwide healthcare business and leader of McKinsey's European healthcare practice.
Meantime, I Holland's new MD, Chris Prideaux, has taken over from Mike Glover who retired in July after more than 20 years of service at the company. An engineer by profession, Prideaux has worked at FKI, David Brown and Textron Corporation.
In the US, drug delivery company MonoSol Rx has named Dr Tushar Misra to the position of vice president of pharmaceutical operations. He joins MonoSol Rx from the specialty pharma company Biovail, where he served as senior director for process development.
MonoSol Rx is developing a fast-dissolve film-based delivery system, FDTAB, a technology that Dr Misra is familiar with from his earlier days at Fuisz Technologies. He has also worked at American Cyanamid and Exxon.
Finally, Brian Bradley has joined over-the-counter drug and contract manufacturer Pharmaceutical Formulations as executive vice president of sales and marketing. He was formerly president and CEO of personal care company USA Labs.